Lytix Biopharma AS (STU:6BG) EBIT: €-6.48 Mil (TTM As of Mar. 2026)


STU:6BG Lytix Biopharma AS STU:6BG
30 GF Score
Price €0.80
GF Value €0.01
! 2 Warning Signs
View Full Analysis

What is Lytix Biopharma AS EBIT?

Lytix Biopharma AS STU:6BG -3.37% 30 EBIT is €-6.48 Mil as of Mar. 2026. GuruFocus rates STU:6BG with a GF Score™ of 30/100 and a GF Value™ of €0.01. The stock has 2 warning signs investors should review.

Lytix Biopharma AS's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €-2.40 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €-6.48 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Lytix Biopharma AS's annualized ROC % for the quarter that ended in Mar. 2026 was -1,098.40%. Lytix Biopharma AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -5,549.13%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Lytix Biopharma AS's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -12.08%.

Lytix Biopharma AS  (STU:6BG) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Lytix Biopharma AS's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-9.6 * ( 1 - 0% )/( (0.784 + 0.964)/ 2 )
=-9.6/0.874
=-1,098.40 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6.889 - 0.961 - ( 6.054 - max(0, 1.568 - 6.712+6.054))
=0.784

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=11.535 - 0.402 - ( 10.762 - max(0, 1.196 - 11.365+10.762))
=0.964

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Lytix Biopharma AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-9.6/( ( (0.176 + max(-1.282, 0)) + (0.17 + max(-0.501, 0)) )/ 2 )
=-9.6/( ( 0.176 + 0.17 )/ 2 )
=-9.6/0.173
=-5,549.13 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.029 + 0 + 0.174) - (0.961 + 0 + 0.524)
=-1.282

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.603 + 0 + 0) - (0.402 + 0 + 0.702)
=-0.501

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Lytix Biopharma AS's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-6.483/53.669
=-12.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lytix Biopharma AS EBIT Related Terms

Lytix Biopharma AS EBIT Historical Data

* Premium members only.

The historical data trend for Lytix Biopharma AS's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lytix Biopharma AS EBIT Chart

Lytix Biopharma AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial -4.73 -5.34 -7.64 -8.01 -5.05

Lytix Biopharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.16 -0.43 -2.08 -1.57 -2.40

STU:6BG vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Lytix Biopharma AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lytix Biopharma AS EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lytix Biopharma AS's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Lytix Biopharma AS's EV-to-EBIT falls into.


STU:6BG
30GF Score
Lytix Biopharma AS STU:6BG
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lytix Biopharma AS EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-6.48 Mil mean?
Lytix Biopharma AS (STU:6BG) has a EBIT of €-6.48 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Lytix Biopharma AS.
Is Lytix Biopharma AS's EBIT too high?
Lytix Biopharma AS's current EBIT is €-6.48 Mil. Overall, Lytix Biopharma AS has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Lytix Biopharma AS's EBIT compare to VRTX and REGN?
Lytix Biopharma AS's EBIT of €-6.48 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Lytix Biopharma AS. Lytix Biopharma AS's current EBIT is €-6.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lytix Biopharma AS stock overvalued right now?
Lytix Biopharma AS (STU:6BG) has a current EBIT of €-6.48 Mil. The stock's GF Value™ is €0.01, compared to a current price of €0.80 — trading 7940% above its estimated fair value. The current EBIT is €-6.48 Mil. Lytix Biopharma AS's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Lytix Biopharma AS (STU:6BG), the current EBIT is €-6.48 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lytix Biopharma AS (STU:6BG) Overvalued in 2026?

Based on GuruFocus' analysis, Lytix Biopharma AS stock appears to be overvalued. The current stock price of €0.80 is trading 7940% above its estimated GF Value™ of €0.01.

Key valuation signals for STU:6BG:

  • EBIT: €-6.48 Mil
  • GF Value™: €0.01 vs. price of €0.80 (7940% above fair value)
  • GF Score™: 30/100 with 2 warning signs

No single metric tells the full story. See the STU:6BG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lytix Biopharma AS Business Description

Other Exchanges LYTIX:Norway
Address Sandakerveien 138, Oslo, NOR, 0484
Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. The company's technology platform is designed to convert immunologically "cold" tumors into "hot" tumors by releasing tumor antigens and activating tumor-specific immune responses. The product pipeline of the company includes LTX-401 and LTX-315. The company operates in Norway and the USA, majority of revenue is from the USA.
30GF Score

Get the complete analysis for STU:6BG

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.80
Price
€0.01
GF Value